A new neoantigen T-cell player has launched with Neogene Therapeutics nabbing a major $110 million series A. The funding haul, a significant sum for a first round, was led by by EcoR1 Capital, Jeito ...
SANTA MONICA, Calif. & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a global biotechnology company focused on discovering, developing, and manufacturing novel, transformative TCR therapies ...
Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies “Engineered T cell therapies have demonstrated ...
AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout. When AstraZeneca scooped up the company back in 2022, ...
AstraZeneca expanded its oncology portfolio Tuesday morning by announcing it reached an agreement to buy Neogene Therapeutics. The British pharma giant is purchasing the clinical-stage biotechnology ...
T-cell therapy company Neogene Therapeutics is being purchased by multinational pharma giant AstraZeneca in a deal potentially worth as much as $320 million that could greatly strengthen the regional ...
NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Neogene Therapeutics, Inc., a pre-clinical stage biotechnology company pioneering a new class of fully personalized neo-antigen T cell therapies to treat cancer, ...
Neogene Co-Founder and CEO Carsten Linnemann, PhD, AstraZeneca has agreed to acquire Neogene Therapeutics for up to $320 million cash, the companies said Tuesday, in a deal intended to bolster the ...
Neogene aims to begin Phase I clinical studies in 2022. Neogene Therapeutics Inc. has raised $110 million in financing to advance the development of neo-antigen T cell therapies to treat various types ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback